Relapsing cytomegalovirus infection in solid organ transplant recipients by Shanahan, A. et al.
Relapsing cytomegalovirus infection in solid organ
transplant recipients
A. Shanahan1, P.N. Malani2,3,4,5, D.R. Kaul2
1Department of Internal Medicine, 2Division of Infectious
Diseases, 3Geriatric Medicine, University of Michigan
Medical School, Ann Arbor, Michigan, USA, 4Veterans Affairs
Ann Arbor Healthcare System, 5Geriatric Research Education
and Clinical Center (GRECC), Ann Arbor, Michigan, USA
A. Shanahan, P.N. Malani, D.R. Kaul. Relapsing cytomegalovirus
infection in solid organ transplant recipients.
Transpl Infect Dis 2009: 11: 513^518. All rights reserved
Abstract: E¡orts to prevent relapsed cytomegalovirus (CMV) disease
among solid organ transplant (SOT) recipients present clinical
challenges. Historically, SOT recipients treated with short courses of
ganciclovir, without documented clearance of viremia, had relapse
rates of 23^33%. Current treatment often includes much longer courses
of valganciclovir, and persistence of viremia at the end of treatment is
rare.We sought to determine the rate and risk factors for relapse under
those treatment conditions. Records of 1760 SOT recipients from
January 2003 to June 2007 were reviewed; 105 cases of CMVviremia
were identi¢ed. Relapse occurred in 20/105 (19%); 50% had end-organ
disease at the time of relapse. Most patients received approximately 3
months of valganciclovir. Clearance of viremia was documented in
19/20 patients with relapse. Multivariable analysis identi¢ed receipt of
a thoracic organ and diabetes mellitus as risk factors for relapse.
Despite long treatment courses with valganciclovir and documented
clearance of viremia, CMVrelapse remains common among SOT
recipients. Better understanding of the epidemiology of CMV
among SOT recipients and validation of risk factors for disease relapse
should be the focus of future prospective trials. Such trials should






























































































During the past decade, improvements have occurred in the
management of cytomegalovirus (CMV) after solid organ
transplantation (SOT).The availability of quantitative whole
blood or plasma-based assays (e.g., real-time polymerase
chain reaction [PCR] or antigenemia assays) has replaced
culture-based assays and improved our ability to diagnose
CMV infection after SOTand monitor response to treatment
(1). These assays may also be used as part of a preemptive
monitoring strategy to prevent CMV disease (2). Further,
the availability of oral valganciclovir has allowed extended
treatment or prophylaxis courses that were previously much
less convenient with intravenous (IV) ganciclovir or the old-
er less bioavailable oral ganciclovir (2).
Despite these advances, CMV remains the leading viral
cause of morbidity and mortality following SOT, and a
number of major questions remain regarding the optimal
management of CMV infection. In particular, the appropri-
ate duration of therapy for CMVdisease has not been well
studied. In previous studies of recurrent CMV disease,
relapse after treatment was observed in 23^33% of cases
(3^8); in most reports a short course (2^3 weeks) of treat-
ment was used (3^5, 7 ). Relapse has been attributed to in-
complete suppression of viremia at the conclusion of
treatment (9), and this has led to the recommendation that
treatment be continued until viremia resolves or for 1week
after viremia resolves (9, 10). No randomized studies, how-
ever, have addressed this question.
In our center, even longer courses of antiviral treatment
(generally 90 days) and monitoring of CMVviremia during
treatment are typically used. Despite these practices, we
noted frequent relapse of CMV infection or disease. Thus,
we sought to determine the incidence and risk factors for
relapse of CMV infection and disease after SOT among
patients treated with prolonged courses of valganciclovir
with documented resolution of viremia before the comple-
tion of treatment.
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The University of Michigan Health System is an 850 -bed
tertiary care facility with an active transplantation pro-
gram. The electronic medical record (CareWeb) of all pa-
tients who received an SOT from January 2003 to June
2007 was reviewed. During that period, a total of 1760
transplants were performed; 1019 kidney, 82 pancreas or
kidney^pancreas, 400 liver, 115 lung, and 144 heart trans-
plants.Those patients with at least 1 CMV PCR41000 cop-
ies/mL (Roche Amplicor CMV Monitor Test, Branchburg,
New Jersey, USA) were included in the study.
CMV prophylactic strategies varied based on time of
transplant and organ transplanted, but all patients at risk
for CMVdisease (donor positive [D 1] and/or recipient pos-
itive [R 1]) received prophylaxis with valganciclovir for 90
days. After 2005, high-risk kidney transplants (D1 , R )
received 6 months of prophylaxis; all other SOT recipients
continued to receive 90 days of valganciclovir, although
total duration of prophylaxis varied somewhat based on the
discretion of the treating physician. Liver transplants re-
ceived valganciclovir, although it is not Food and Drug Ad-
ministration approved for this indication. The ganciclovir
and valganciclovir dose was adjusted for renal function.
Immunosuppression protocols varied, but recipients of
lung and liver transplants did not receive induction
immunosuppression. Heart transplant patients with base-
line renal dysfunction or those considered to be at risk for
renal dysfunction (e.g., prolonged operative time) and at
high immunologic risk for rejection received induction
immunosuppression with muromonab-CD3 (OKT3) 2.5 mg
IV daily  3^10 days or thymoglobulin 100^125 mg  2
days then 50 mg  6^10 days. High-risk kidney transplant
recipients (African-American, previous transplant, panel
reactive antibodies 430%, unrelated living donor) re-
ceived thymoglobulin. Low-risk patientswith delayed graft
function received basiliximab. For maintenance immuno-
suppression, most renal, heart, and lung transplant recipi-
ents received mycophenolate mofetil, cyclosporine or
tacrolimus, and prednisone. In most liver recipients,
immunosuppressionwas reduced over 2^3 months to tacro-
limus alone.This study was approved by the University of
Michigan Health System Institutional Review Board.
Data collection and de¢nitions
Transplant recipients with at least 1 CMV PCR41000 cop-
ies/mL were identi¢ed as having CMV infection and in-
cluded in the study. Patients with CMV disease but
without viremia were not included. CMV disease was de-
¢ned as patients with CMVviremia and a febrile syndrome
without an alternative explanation, or patients with CMV
viremia and clinical or histological evidence of end-organ
involvement. No routine monitoring strategy for CMV in-
fection was used, and all CMV PCR tests and other studies
were obtained at the discretion of treating physicians.
Relapsed CMV infection was de¢ned as CMV viremia
(41000 copies/mL) recurring within 100 days of complet-
ing treatment. Relapsed CMV disease utilized the same
de¢nitions as in the preceding paragraph. Demographic
and clinical datawere collected in all patients with CMV in-
fection or disease including prednisone dose, donor and re-
cipient CMV serologies, co-morbidities, rejection therapy,
duration of CMV prophylaxis, whether or not viremia was
documented to have cleared, and time to recurrence. CMV
treatment data including duration of therapy were also
collected.
CMV treatment protocols
Renal transplant patients with CMV disease received oral
valganciclovir 900 mg orally twice a day for 21 days fol-
lowed by 900 mg daily to complete a total 90 -day treatment
course. The dose was adjusted as appropriate for renal
function. Patients unable to reliably take oral val-
ganciclovir received IV ganciclovir (5 mg/kg twice a day,
adjusted for renal function) until able to take oral therapy.
Duration of treatment and dosing for recipients of other
transplants was based on the discretion of the treating phy-
sician. For all patients, CMVmonitoring both during treat-
ment and after conclusion of treatment varied, based on the
treating physician and clinical circumstances.
Data analysis
Risk factors for relapse of infection or disease were calcu-
lated. A separate calculation of risk factors was performed
and limited to patients who relapsed with CMVdisease (re-
lapse of infection alone was excluded). Univariate analysis
using t-tests orW|lcoxon’s rank-sum performed for continu-
ous variables and chi-square or Fisher’s exact test for cate-
gorical variables identi¢ed risk factors for CMV relapse.
Two-tailed P-value  0.05 was considered statistically sig-
ni¢cant. Crude odds ratio (OR) and 95% con¢dence inter-
val (CI) were calculated for categorical variables. Crude
ORs for continuous variables were obtained using simple
logistic regression.Variables that were signi¢cant to a P-va-
lue of 0.20 as well as those variables that had a priori clini-
cal signi¢cance were then analyzed using multivariate
logistic regression modeling. All statistical analysis was
performed using SAS 9.1 (SAS Institute Inc., Cary, North
Carolina, USA).
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Results
We identi¢ed 105 patients with CMVviremia among whom
20 (19%) demonstrated relapse. Of the patients with re-
lapse, 10/20 (50%) had CMV disease and 10/20 (50%) had
CMV infection without disease. In 19/20 (95%) of relapsed
cases, viremia was documented to have cleared at the com-
pletion of antiviral therapy. In cases without relapse, 59/85
(69%) cleared viremia, 2/85 (2%) did not clear viremia, and
in 24/85 (28%) further studies were not obtained to docu-
ment clearance.These patients did not have clinical symp-
toms prompting a repeat CMV PCR. Four of these 24
patients died; no others were lost to follow up. Risk factors
for relapsed infection identi¢ed by univariate analysis in-
cluded advancing age, diabetes mellitus, and receipt of a
chest as opposed to an abdominal organ (Table 1). Relapse
rates were highest among recipients of heart transplants 6/
16 (38%) and lowest for kidney transplant recipients
6/51 (11%) (Table 1). In multivariate analysis, diabetes mel-
litus (adjusted OR 4.1, 95% CI [1.3^13] P5 0.02) and receipt
of thoracic organ (adjusted OR 3.6, 95% CI [1.2^10.6]
P5 0.02) were signi¢cant (Table 2). Duration of treatment
for the initial episode of CMVviremia did not di¡er signi¢-
Characteristics of solid organ transplant recipients with cytomegalovirus (CMV) viremia
Characteristic
No relapse Relapse
OR (95% CI) P-value85 (81%) 20 (19%)
Demographics
Age1 48 (range 21^73) 52 (range 36^69) 1.05 (1.0^1.1) 0.05
Female 30 (35%) 8 (40%) 1.2 (0.5^3.3) 0.90
White race 71 (84%) 20 (100%) 8.3 (0.5^145) 0.08
Co-morbidities
Diabetes 38 (45%) 14 (70%) 3.7 (1.2^11.1) 0.01
Renal insu⁄ciency (serum creatinine41.5) 23 (27%) 6 (30%) 1.6 (0.4^3.4) 0.79
Transplanted organ
Renal 51 6 (11%) 0.3 (0.1^0.8) 0.03
Renal and pancreas 3 1 (25%) 1.4 (0.14^14.6) 0.99
Pancreas alone 2 1 (33%) 2.2 (0.2^25.3) 0.99
Liver 9 2 (18%) 0.9 (0.2^4.7) 0.99
Lung 10 4 (29%) 1.9 (0.5^6.7) 0.99
Heart 10 6 (38%) 3.2 (1.0^10.3) 0.08
Chest organ 20 10 (33%) 3.3 (1.2^8.9) 0.02
Abdominal organ 65 10 (13%) 0.3 (0.1^0.8) 0.02
CMV status
High risk 58 (68%) 13 (65%) 1.2 (0.4^3.6) 0.99
Recipient positive 24 (28%) 5 (25%) 0.9 (0.3^2.6) 0.99
Donor and recipient negative 2 (2%) 0 0.8 (0.04^17.6) 0.99
CMV status unknown 1 (1%) 2 (10%) 9.3 (0.8^109) 0.18
Induction immunosuppression
Cell depleting induction 37 (44%) 11 (55%) 1.6 (0.6^4.2) 0.50
IL-2R antagonist 23 (27%) 4 (20%) 0.7 (0.2^2.2) 0.74
No induction 25 (29%) 5 (25%) 0.8 (0.26^2.4) 0.93
Maintenance immunosuppression
Prednisone dose at diagnosis (mg) 10 (range 0^60) 10 (range 0^40) 0.94
Prednisone dose at completion of treatment (mg) 10 (range 0^20) 10 (range 0^15) 0.77
Absolute lymphocyte count at diagnosis 0.84  1.0 0.73  1.3 0.70
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cantly between recipients of di¡erent organs and was as
follows: heart median 83 days (range 30^360), kidney me-
dian 90 days (range 14^205), liver median 38 days (range 4^
187 ), and lung median 104 days (range 14^365).
Receipt of rejection therapy was not di¡erent between
patients with relapse (2/20, 10%) and without relapse (9/
85, 11%). Although the number of patients with high-risk
serostatus (D 1 , R ) was similar among abdominal and
thoracic organ recipients (60% thoracic and 74% abdomi-
nal), thoracic organ recipients with high-risk serostatus
were much more likely to develop CMV relapse (8/18 [44%]
versus 5/53 [9%], OR 7.7 [2.1^28.4], P5 0.005).
Aunivariate analysis of the 10 patients with relapsed dis-
ease (but excluding those with infection without disease)
was performed using the same variables. The presence of
diabetes mellitus (8/10 [80%] versus 45/95 [47%], OR 4.4,
95% CI [0.9^22] P5 0.09) was not signi¢cant, and age was
not a risk factor for relapse. Recipients of renal transplants
(without pancreas) were less likely to relapse than recipi-
ents of other organs (2/10 [20%] versus 55/95 [58%] OR 0.2
95% CI [0.04^0.9] P5 0.05), and recipients of chest organs
were more likely to relapse (6/10 [60%] versus 24/95 [25%],
OR 4.4, 95% CI [1.2^17.1] P5 0.05). Of the 10 patients with
relapsed CMVdisease, CMVsyndrome was present in 4, en-
teritis in 3, and pneumonitis in 3. Among all relapsed pa-
tients, the median CMV viral load at time of relapse was
6208 copies/mL, and relapse occurred a mean of 38 days
and a median of 60 days after completing initial treatment
(range 7^98 days). No ganciclovir resistance was noted
among relapsed patients, and all patients were treated with
either ganciclovir or valganciclovir.
Discussion
Despite extended courses of treatment with oral val-
ganciclovir and documented resolution of viremia in all
but 1 case, a relatively high rate of relapse of CMV infection




OR (95% CI) P-value85 (81%) 20 (19%)
Duration of CMV prophylaxis
None 4 (5%) 0 0.4 (0.02^8.5) 0.85
o90 days 4 (5%) 3 (15%) 3.5 (0.7^17.4) 0.99
90^130 days 63 (74%) 13 (65%) 1.0 (0.4^2.2) 0.87
135^180 days 9 (11%) 4 (20%) 2.1 (0.6^7.7) 0.44
4180 days 1 (1%) 0 1.3 (0.05^35) 0.99
Unknown 4 (5%) 0 0.4 (0.02^8.5) 0.85
Days post transplant to time of CMV diagnosis (median)2 167 180 0.29
Clinical evidence for end organ disease 52 (61%) 16 (80%) 0.42 (0.16^1.1) 0.14
Peak CMV copies/mL (median)2 22,700 (range 10,400^100,000) 23,200 (range 1270^100,000) 0.21
Peak CMV copied/mL4100,000 15 (18%) 4 (20%) 1.2 (0.34^4.0) 0.99
Treatment duration (days) 93.8  77 84.2  54 0.59
1OR for age reported for 1-year unit.
2Results not normally distributed, thus median results reported and compared byWilcoxon’s rank-sum test.
High risk, donor positive, recipient negative; OR, odds ratio; CI, con¢dence interval.
Table1
Multivariable analysis of the association of select patient characteristics
on relapsed cytomegalovirus (CMV) infection among solid organ
transplant recipients
Characteristic aOR (95% CI)1 P-value
Age2 1.05 (1.0^1.1) 0.07
Diabetes mellitus 4.1 (1.3^13) 0.02
Receipt of thoracic organ 3.6 (1.2^10.6) 0.02
1Adjusted odds ratios (aOR) and 95% con¢dence intervals (CI) are based
on amultivariable logistic regression adjusting for age, diabetesmellitus,
receipt of a thoracic organ, high-risk CMV serostatus, and prednisone
dose at diagnosis of CMV.
2OR for age reported for 1-year unit.
Table 2
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CMV viremia or disease and high-risk serostatus did not
appear to be associated with a reduced risk of relapse. Re-
cipients of thoracic organs were at higher risk of relapse
than recipients of abdominal organs, and high-risk serosta-
tus (D 1 , R ) recipients of chest organs experienced a
particularly high rate of relapse. Half of relapsed cases
had CMVdisease at the time of relapse, and half had CMV
infection without disease.
Very few studies have addressed relapsing CMV infec-
tion among SOT recipients, with reported relapse rates of
23^33% (Table 3). The majority of these studies were con-
ducted before the availability of highly bioavailable oral
valganciclovir, which makes longer treatment courses
more feasible. In 4 of the 6 studies inTable 3, treatment con-
sisted of short courses of IVganciclovir, and viremia was
commonly present (or not proven to have resolved) at the
time of completion of treatment (3^5, 7 ). The overall rate of
CMV relapse observed in our study (19%) is only margin-
ally lower. If the rate among kidney transplants alone is
compared, however, our rate of 6/51 (11%) shows a clear
trend toward being lower than the 25% relapse rate ob-
served by Franco et al. (4).
Two of the 6 studies prescribed longer courses of treat-
ment.Turgeon et al. (8) followed a 2^3-week course of IVgan-
ciclovir with 2^3 months of the older, less bioavailable oral
preparation of ganciclovir, but relapse remained high at
27%. In the recent report from Levitsky et al. (6), 28 patients
received extended treatment (median 119 days IV ga-
nciclovir followed by oral valganciclovir or median 104
days valganciclovir alone), and an even higher relapse rate
of 33%was reported.The majority of recurrences, however,
were asymptomatic and not treated with additional antivi-
ral therapy. By contrast, among our patients, 50% had end-
organ disease at the time of relapse. In our center, monitor-
ing for CMV viremia after completion of treatment varied
based on treating physician preference. This variability
may account for di¡erences in the rate of asymptomatic
CMV infection and CMVdisease observed among patients
with relapse.
Risk factors for relapsed disease have varied across pre-
vious studies (Table 3).Two studies identify failure to clear
viremia as a risk factor for relapse (4, 5), and it is certainly
biologically plausible to expect that CMV would be more
likely to relapse among patients with viremia after complet-
ing treatment.Thus, it is somewhat surprising that, despite
a relatively high recurrence rate, virtually all patients with
relapse in our study had resolution of viremia at completion
of primary therapy.
In addition, our study identi¢ed receipt of a chest organ
as a risk factor for relapse. In particular, high-risk serosta-
tus thoracic organ recipients had a 44% relapse rate. Lung
transplant recipients in particular are known to be at high-
er risk for CMVdisease (10), and perhaps the same factors
that put them at risk for initial disease account for the
increased risk for relapsed disease.We also noted that the
initial prednisone dose at the time of initial CMVdiagnosis
Review of published studies of relapsing cytomegalovirus (CMV) disease in solid organ transplant (SOT) recipients
Study Population Treatment Relapse rate Risk factors for relapse Comments
Franco et al. (4) 49 renal transplant
recipients
2 weeks of IV ganciclovir 12/49 (24.5%) Failure to clear viremia
Acute rejection
Humar et al. (5) 52 SOT recipients (liver
35, kidney 7, lung 7,
other 3)
2^3 weeks of IV ganciclovir 12/52 (23.1%) Failure to clear viremia
T|me to clearance
Slow decrease of viral load in ¢rst
week of treatment
Sia et al. (7) 24 SOT recipients
(heart, liver, kidney)
2 weeks of IV gancicloivir 8/33 (33%) High-risk serostatus
Higher pre- and post-treatment
viral loads
25% had persistent
viremia after 14 days
treatment
Turgeon et al. (8) 19 kidney, 18 liver
transplant recipients
2^3 weeks of IV ganciclovir,
then 2^3 months of oral
ganciclovir (2 g/day)
10/37 (27%) High-risk serostatus
Higher peak antigenemia value
during treatment
Falagas et al. (3) 41 liver transplant
recipients
81days of IV ganciclovir 11/41 (27%) Presence of multiorgan disease
CMV pneumonia
Levitsky et al. (6) 28 SOT (kidney, liver,
heart, lung; 6 received
chest organ)
119 days of IV ganciclovir
followed by oral valgan or 104
days of valgancyclovir
alone
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is higher among patients with thoracic organs (13.4  15
versus 9.7  2.4 mg, P5 0.03). In the cohort as awhole, how-
ever, prednisone dose did not show signi¢cance in either
univariate analysis or multivariate regression models of
risk factors for relapse.The dose at the end of therapy was
not di¡erent between the groups.
In the univariate analysis, increasing age was also iden-
ti¢ed as a risk factor, but was of only borderline signi¢-
cance in the multivariate analysis. Cell-mediated
immunity is known to wane with increasing age (11), and
this may have accounted for this association. Impaired im-
munity may also explain the identi¢cation of diabetes mel-
litus as a risk factor for relapse.These risk factors deserve
additional consideration in future studies.
Our study has a number of important limitations. Com-
parison of rates of CMV infection or disease from one study
to another are complicated by changes in diagnostic tests
available over time as well as center-to-center di¡erences
in practice patterns for CMV monitoring after completion
of treatment. No set protocol for monitoring is established
at our institution, thus the approach varied depending on
physician preference. These practices may result in an as-
certainment bias that may a¡ect the number of cases of re-
lapse diagnosed. For example, routine monitoring for CMV
viremia or antigenemiawould likely identify some patients
who might resolve their viremiawithout further treatment.
In addition, the management of CMV infection and disease
(including duration of treatment) varied considerably by
type of organ aswell as frompatient to patient transplanted
with the same organ. Such di¡erences may have accounted
for the higher risk of relapse observed in recipients of chest
organs. In order to account for this, we also analyzed by the
endpoint of CMVdisease, as ascertainment bias would be
expected to be less of factor in patients presenting with
clinical symptoms suggestive of CMVdisease. In this anal-
ysis, recipients of chest organs were at higher risk of re-
lapse than renal recipients, but diabetes mellitus and age
were not signi¢cant. Finally, we only studied episodes of
CMVviremia, but did not attempt to identify patients with
CMVdisease who did not have viremia.
Our results suggest that, despite long treatment courses
with oral valganciclovir and resolution of viremia, CMVre-
lapse remains relatively common among SOT recipients.
Recipients of abdominal organs, however, may be at lower
risk than recipients of thoracic organs. Patients at higher
risk of relapse (e.g., older recipients of thoracic organs or
patients with diabetes) may bene¢t from more intensive
monitoring for relapse. Despite the limitations of our study
design, the 19% CMV relapse rate is notable. Future pro-
spective, randomized trials of di¡erent durations of treat-
ment (e.g., 1 versus 4 weeks after resolution of viremia) are
warranted. Another strategy that has been suggested to in-
dividualize prophylaxis involves the use of patient-speci¢c
markers of CMV cell-mediated immunity (12). A similar
strategy could be tried to predict risk of relapse. In any
case, such trials should include extended monitoring for re-
lapse (up to 100 days) and a quantitative threshold (e.g.,
45,000 copies/mL on 2 separate measurements) for treat-
ing relapse in patients with asymptomatic viremia.
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